Pegfilgrastim (Pegylated Filgrastim) | MedexInfo
Pegfilgrastim (Pegylated Filgrastim)
Rx Only
Generic NamePegfilgrastim
Therapeutic ClassG-CSF (Granulocyte Colony-Stimulating Factor)
Common Dose6 mg SC once per chemotherapy cycle
Max / 24hAs per protocol
PregnancyCategory C
Indications ▼
Prevention of chemotherapy-induced neutropenia
Treatment of severe chronic neutropenia
Peripheral blood progenitor cell mobilization
Mechanism & Pharmacokinetics ▼
Mechanism: Stimulates proliferation, differentiation, and activation of neutrophil precursors, enhancing neutrophil recovery after myelosuppressive therapy.
Pharmacokinetics: Pegylation prolongs half-life (~42 hours). Administered SC; metabolized by neutrophil-mediated clearance; steady-state achieved after single dose per chemotherapy cycle.
Dosage & Administration ▼
| Patient Category | Recommended Dose | Max / 24h |
|---|---|---|
| Adults | 6 mg SC once per chemotherapy cycle, 24 hours after chemotherapy | As per protocol |
| Children (≥2 years) | 100 mcg/kg SC once per cycle | As per protocol |
| Hepatic/Renal Impairment | No adjustment usually required; monitor ANC | As per clinical guidance |
Note: Administer SC in upper arm, abdomen, or thigh. Do not administer within 24 hours before or after chemotherapy. Monitor ANC (absolute neutrophil count) regularly.
Side Effects ▼
Common: Bone pain, fatigue, mild fever
Occasional: Headache, nausea, diarrhea
Rare: Splenic rupture, acute respiratory distress, severe allergic reactions
Contraindications ▼
Hypersensitivity to pegfilgrastim or filgrastim
History of splenic enlargement or rupture with G-CSF therapy
Drug Interaction ▼
Chemotherapy: avoid same-day administration
Other hematopoietic growth factors: monitor blood counts
Pregnancy & Lactation ▼
Category C; use only if benefit outweighs risk
Excretion in breast milk unknown; monitor infant if used during lactation
Clinical / Research Summary ▼
Effectively reduces incidence and duration of chemotherapy-induced neutropenia.
Once-per-cycle dosing improves patient convenience and compliance.
Monitor for bone pain and splenic enlargement to reduce rare complications.
Patient Counseling Points ▼
Rotate injection sites to reduce local irritation.
Report persistent bone pain or abdominal fullness.
Do not self-administer within 24 hours of chemotherapy.
Storage & Handling ▼
Store refrigerated 2–8°C; do not freeze
Protect from light
Keep out of reach of children
Brand Names (Bangladesh & Global) ▼
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult a qualified healthcare provider.
Reference Hubs:
.png)
